Biotechnology Businesses for Sale and Investment

Our brand is the world’s first instant methanol detection test, designed to protect consumers from deadly counterfeit alcohol. Our rapid-detection strip provides a fast, portable, and affordable solution for travelers, bars, hotels, and government agencies. HQ: Planned Dubai launch for cost-effective operations, global scalability, and safety of transactions. Market opportunity: $60B+ counterfeit alcohol crisis worldwide (1,000s of people die from methanol poisoning each year! and there is no way to test the drinks) Revenue model: • Direct-to-consumer (DTC): Sold online (Amazon, TikTok Shop, website) through major online retailers worldwide. • Bulk B2B sales: Hotels, universities, hospitals, pharmacies, retailers, train stations, bars, duty-free retailers. Globally. • Licensing deals: Partnering with biotech firms & alcohol brands for distribution. Projected price: ~$19.99 per pack, we must aim to have a 70% margin. Projected sales growth: •Year 1: 50K units → $1M revenue. •Year 2: 250K units → $5M revenue. •Year 3: 1M+ units → $20M+ revenue. Exit strategy: Sell to a biotech or alcohol safety giant etc for $50M+ or license the technology for passive royalties. Promoter experience & business relationships: • Founder: Experienced entrepreneur with expertise in luxury branding, viral marketing, and scaling consumer products with the globally recognized superstars behind the previous brand I have developed. • Scientific & business team: Partnering with chemists & biotech advisors to ensure product reliability. • Distribution talks: Engaging bars, airlines, hotels, etc. • Investor network: Seeking 1-2 strategic investors to fund final development and global launch. This product is positioned to disrupt a billion-dollar problem and scale as the go-to alcohol safety brand worldwide. Some of the brightest minds in biotech and science will be on board. The product is not medicine and does not need to be FDA-approved as we will market it as a consumer product (like pregnancy tests). The product will deliver a 90% accuracy which is enough to save millions of lives. This is a once-in-a-lifetime opportunity and we are applying for patents already.

Situated in Fremont, this business specializes in manufacturing assay kits for biochemicals, enzymes, and ions, serving primarily the life science and biotechnology sectors. - The company focuses on providing research products that are designed to be user-friendly, highly reproducible, and cost-effective, potentially advancing research in serious health conditions such as cancer, diabetes, and neurodegenerative diseases. - With a global network of 30-35 distributors, the company exports 90% of its products mainly to European and Asian markets, including key countries like China, Korea, and Japan. - The production capacity stands at manufacturing 500 kits per day, ensuring steady supply capabilities to meet the needs of international research communities. - Orders are fulfilled on a weekly basis, facilitating consistent supply and robust support for ongoing research projects worldwide. - The business is not yet profitable, as its revenue is being reinvested into expansion and growth efforts. - By focusing on quality and affordability, the company distinguishes itself as a competitive player in the assay kit market, supporting vital research across continents.

The company is strategically positioned in the biotechnology sector, with plans to specialize in high-demand services such as flow cytometry and cell culture, tailored to support pharmaceutical, biotech, and diagnostic companies. - Despite being registered 4 years ago, the company has yet to start operations but has laid the groundwork through strategic collaborations and grant submissions totalling approximately USD 40 million, showcasing a strong potential for funding acquisition. - The promoter's extensive background, with a PhD in cell biology and two decades of research experience, provides a strong foundation for the company's technical expertise and leadership. - Possession of distribution rights for crucial research kits and therapeutic proteins indicates early-stage readiness to supply essential products to the research community. - The company maintains strategic collaborations with antibody-based firms, enhancing its capability to provide comprehensive solutions for advanced therapeutic and research needs. - Haverhill, the company's location, provides access to a strategic geographical position that can facilitate partnerships with key biotech and pharmaceutical players. - The planned service offerings, including advanced flow cytometry and specialized cell culture services, underscore the company's commitment to supporting cutting-edge research with reliable and customizable solutions.

Established player in the biomedical devices sector, operating from Chennai with a focus on servicing bio-medical equipment and consultancy services. - Currently employs a dedicated team of 8 skilled professionals committed to excellence in service delivery. - Recognized as one of the top 25 companies with innovative products by the Wadhwani Foundation CEO, highlighting its commitment to quality and innovation. - Signed MOU with VIT University, Vellore, and IITM for internship training programs for students, fostering educational collaboration and real-world experience. - Successfully served over 550 hospitals, showcasing a strong market presence and customer trust. - Maintains strategic partnerships with Original Equipment Manufacturers (OEMs) to ensure seamless device procurement. - The promoter brings 33 years of industry experience, having held key positions in leading hospitals and multinational corporations, enhancing business credibility. - Registered with the Ministry of Corporate Affairs (MCA), ensuring compliance with legal frameworks within the industry.

Industry overview: The business will operate in the nutraceutical sector, which is witnessing significant growth due to increasing health awareness and demand for nutritional supplements. - Strategic location: Based in Udupi, the company will be well-positioned to leverage local resources while also accessing global markets. - Innovative product offering: The company will specialise in the manufacturing of oral supplements aimed at treating various health complications and underlying disease conditions, catering to a diverse range of consumer needs. - Diverse client base: Potential clients include the National Health Service (NHS), pharmacies, health stores, and multinational corporations, allowing for both B2B and B2C sales strategies. - Experienced leadership: The promoter brings over 20 years of experience in the nutraceutical industry, providing a strong foundation for the company's growth and innovation. - Growth potential: With a focus on innovation and export, the company has the potential to evolve into a multibillion-dollar enterprise, tapping into the growing global demand for health supplements. - Regulatory compliance - the company is registered in the MCA and is yet to acquire the necessary licenses and approvals for manufacturing. - The promoter correctly resides in the UK.

Planning to establish a cannabis plantation to produce anesthetic drugs. - Seeking foreign investors to comply with the local law, which mandates that only foreigners can hold a license for cannabis plantations. - The promoter is an Ayurvedic doctor with 30 years of experience in the industry. - We will be applying for licenses, and only foreigners are eligible to hold them. - Our plan is to establish a cannabis plantation and export cannabis anesthetic drugs through distributors worldwide. - The drugs will be specifically formulated for anesthesia purposes.

A deep-tech company based in Flanders, Belgium, was established in February, 2 years ago. We specialize in delivering Artificial Intelligence (AI) and advanced Modeling & Simulation (M&S) solutions to the pharmaceutical industry, operating at the intersection of computational science and drug development. - Our core offerings include a proprietary Software-as-a-Service (SaaS) platform and specialized consulting services spanning the entire drug development lifecycle—from early discovery to late-stage development—including market access, pricing, and value demonstration for novel therapies. - We serve a diverse global client base across the pharmaceutical, biotechnology, and medical device sectors. - Our clientele includes key players such as Deloitte Belgium, UCB Pharma, Fresenius Kabi, B. Braun, and Translucency Ltd. - Through data-driven insights, we enable these partners to accelerate product development and optimize their market strategies. - The company has demonstrated consistent operational growth since its inception. Our revenues reflect this trajectory, with €76,000 reported two years ago, €118,062 last year, and a projected €164,200 for this fiscal year (ending in June). - The company maintains a stable financial position, underpinned by a net working capital of approximately €50,000, and has been awarded a €50,000 grant by VLAIO (Flanders Agency for Innovation and Entrepreneurship) to further develop our platform.

1. Greece's advantageous climate and geographic location make it an ideal setting for the development of a cannabis industry, leveraging abundant sunlight and easy access to European markets. 2. The company has received a substantial grant of EUR 840,000 from the development law, providing a financial boost with no repayment expectations. 3. Possessing a medical cannabis license enabling the production of up to 45 different products, the business has the potential to be among the top 10 distributors in Greece, positioning itself for significant market share. 4. The company holds licenses for cultivating and processing medicinal cannabis plants, focusing on the cultivation and processing of medicinal cannabis on a plot area of approximately 9,000 m2 in Nea Anchialos. 5. With the intention to achieve one of the highest levels of medical cannabis production in Europe over the next five years, the business has the potential to generate a gross profit of over 5 million euros. 6. The company has obtained the necessary legal documentation and licenses, including the first Installation approval license, to expedite the construction of a successful pharmaceutical cannabis facility, positioning it ahead of many others in the industry. 7. As a pioneer in Greece's medical cannabis sector, the business has the opportunity to capitalize on the location and the needs.